MAIA Biotechnology Inc. Cash Flow Conversion Efficiency
MAIA Biotechnology Inc. cash flow conversion efficiency. Based on the latest financial reports, MAIA Biotechnology Inc. (MAIA) has a cash flow conversion efficiency ratio of -0.191x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.31 Million) by net assets ($27.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of MAIA Biotechnology Inc. (2019–2025)
Cash flow conversion efficiency of MAIA Biotechnology Inc. from 2019 to 2025. This chart illustrates how MAIA Biotechnology Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View MAIA Biotechnology Inc. stock quote for real-time trading data and today's change.
MAIA Biotechnology Inc. Cash Flow Conversion Ratio Explained
MAIA Biotechnology Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
MAIA Biotechnology Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MAIA Biotechnology Inc. ranked by their cash flow conversion efficiency. Also see how much is MAIA Biotechnology Inc. worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asetek A/S
F:A31
|
0.018x |
|
APEX International Financial Engineering Res & Tech Co Ltd
TWO:5210
|
0.016x |
|
Aerovate Therapeutics Inc
NASDAQ:AVTE
|
-0.032x |
|
Jinhui Shipping and Transportation Limited
OL:JIN
|
-0.007x |
|
Saunders International Ltd
AU:SND
|
0.229x |
|
Wintergreen Acquisition Corp. Ordinary Shares
NASDAQ:WTG
|
-0.003x |
|
Karel Elektronik Sanayi ve Ticaret AS
IS:KAREL
|
0.171x |
|
EXA E&C Inc
KQ:054940
|
0.179x |
Annual Cash Flow Conversion Efficiency for MAIA Biotechnology Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of MAIA Biotechnology Inc. from 2019 to 2025. Review MAIA Biotechnology Inc. free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.38 Million | $-18.84 Million | -7.932x | -83.57% |
| 2024-12-31 | $3.63 Million | $-15.70 Million | -4.321x | +84.22% |
| 2023-12-31 | $477.51K | $-13.07 Million | -27.373x | -1825.30% |
| 2022-12-31 | $8.51 Million | $-12.10 Million | -1.422x | -216.61% |
| 2021-12-31 | $9.18 Million | $-4.12 Million | -0.449x | -139.36% |
| 2020-12-31 | $-1.62 Million | $-1.84 Million | 1.141x | +196.58% |
| 2019-12-31 | $1.32 Million | $-1.57 Million | -1.181x | -- |
About MAIA Biotechnology Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illin… Read more